Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts
19 Junho 2019 - 9:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage
biopharmaceutical company pioneering a novel disease-modifying
therapeutic approach to treat a key underlying cause of Alzheimer’s
and other degenerative diseases, today announced four new
additions to its Clinical Advisory Board (CAB). Jeffrey Cummings,
M.D., Sc.D., David Hosford M.D., Ph.D., Lon Schneider, M.D., M.S.,
and Pierre N. Tariot, M.D. join the CAB with deep and diverse
experience in central nervous system (CNS) drug development. The
newly expanded CAB will support Cortexyme as its lead
investigational gingipain inhibitor, COR388, moves through phase
2/3 clinical development as a potential treatment for patients with
mild to moderate Alzheimer’s disease.
“The growing data from Cortexyme and other researchers around
the gingipain hypothesis is compelling,” said Lon Schneider, M.D.,
M.S., a new member of the CAB and Professor of Psychiatry,
Neurology, and Gerontology at the Keck School of Medicine of the
University of Southern California. “I look forward to collaborating
with my colleagues on the Cortexyme CAB to advise the company as it
evaluates this upstream therapeutic approach, both through the
ongoing GAIN trial and future clinical development work.”
Commenting on the expansion of the CAB, Michael Detke, M.D.,
Ph.D., Chief Medical Officer of Cortexyme said: “Cortexyme has
benefited greatly from our Clinical Advisory Board’s input into the
GAIN trial design, and we are excited to expand the group with the
addition of Drs. Cummings, Hosford, Schneider, and Tariot, who
collectively bring world-class expertise in CNS disease research,
drug development, and regulatory affairs. We look forward to
working together to efficiently advance COR388 for the benefit of
Alzheimer’s patients.”
Additions to Cortexyme’s Clinical Advisory
Board:
- Jeffrey Cummings, M.D., Sc.D.,
is a longtime Alzheimer’s researcher and clinical trial leader
committed to developing new therapies for diseases of the brain and
studying the interface of neuroscience and society. Dr. Cummings is
Research Professor in the Department of Brain Health at University
of Nevada Las Vegas and founding director of Cleveland Clinic Lou
Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland,
Ohio. He is a professor of medicine (neurology) at the
Cleveland Clinic Lerner College of Medicine of Case Western Reserve
University. He is the principal investigator/director of the
NIH/NIGMS-funded Center for Neurodegeneration and Translational
Neuroscience.
- David Hosford M.D., Ph.D. is the
chief medical officer (CMO) at Kingsfoil Pharmavision, a
biopharmaceutical consultancy specializing in strategic drug
development advice and regulatory pathway guidance. He formerly
served as an FDA clinical reviewer in its Division of Neurology
Products; as CMO at Kowa Research Institute; as a senior strategic
medical lead (CNS) at Quintiles; as the Vice President for
Clinical Development and Regulatory Affairs at Targacept, Inc.; and
in many discovery and development roles across multiple therapeutic
areas at GlaxoSmithKline.
- Lon Schneider, M.D., M.S. is a
recognized expert on Alzheimer’s disease and its treatment,
late-in-life depression, and drug development. He is a professor of
Psychiatry, Neurology, and Gerontology at the Keck School of
Medicine of the University of Southern California. Dr. Schneider
also serves as the director of the California Alzheimer’s Disease
Center and the USC Department of Psychiatry Geriatric Studies
Center, as well as the co-director of the clinical core of the
university’s Alzheimer’s Disease Research Center, which is
supported by the NIH.
- Pierre N. Tariot, M.D. serves as
the director of the Banner Alzheimer’s Institute, a component of
the research organization of Banner Health, one of the largest
non-profit healthcare systems in the United States. Dr. Tariot is
also a research professor of psychiatry at the University of
Arizona College of Medicine. A member of the American College
of Neuropsychopharmacology, he has earned multiple awards for
his research, including the American Geriatrics Society
New Investigator Award for Neuroscience and an NIMH Geriatric
Mental Health Academic Award.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering a novel disease-modifying
therapeutic approach to treat a key underlying cause of Alzheimer’s
disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead
investigational medicine, COR388, is the subject of the GAIN trial,
an ongoing Phase 2/3 clinical study in patients with mild to
moderate Alzheimer’s disease. More information about the trial can
be found at www.GAINtrial.com. To learn more about Cortexyme, visit
www.cortexyme.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9,
2019 and Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission on June 12, 2019.
Forward-looking statements contained in this press release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190619005410/en/
Hal MackinsFor Cortexyme, Inc.hal@torchcomllc.com(415)
994-0040
Quince Therapeutics (NASDAQ:QNCX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Quince Therapeutics (NASDAQ:QNCX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024